Amgen Inc
NASDAQ:AMGN

Watchlist Manager
Amgen Inc Logo
Amgen Inc
NASDAQ:AMGN
Watchlist
Price: 340.68 USD -1.37% Market Closed
Market Cap: 183.4B USD
Section:
 

Relative Value

The Relative Value of one AMGN stock under the Base Case scenario is 338.99 USD. Compared to the current market price of 340.68 USD, Amgen Inc is Fairly Valued.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AMGN Relative Value
Base Case
338.99 USD
Fairly Valued
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.1
P/S
P/S
Price to Sales
5.1
vs History
17
vs Industry
61
Median 3Y
5
Median 5Y
4.7
Industry
7.8
Forward
5
More Details
26.3
P/E
P/E
Price to Earnings
26.3
vs History
20
vs Industry
4
Median 3Y
23.6
Median 5Y
20
Industry
24.4
Forward
15.9
More Details
14.1
P/OCF
P/OCF
Price to OCF
14.1
vs History
23
vs Industry
11
Median 3Y
13.5
Median 5Y
12.9
Industry
21.4
More Details
14
P/FCFE
P/FCFE
Price to FCFE
14
vs History
36
vs Industry
4
Median 3Y
13.8
Median 5Y
11.6
Industry
23.2
More Details
19.2
P/B
P/B
Price to Book Value
19.2
vs History
58
vs Industry
2
Median 3Y
23.6
Median 5Y
21.5
Industry
3.3
More Details
6.3
EV/S
EV/S
Enterprise Value to Sales
6.3
vs History
19
vs Industry
45
Median 3Y
6.1
Median 5Y
5.8
Industry
8.4
Forward
6.2
More Details
8.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
8.8
vs History
26
vs Industry
39
Median 3Y
8.7
Median 5Y
7.9
Industry
10.3
More Details
18.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
18.7
vs History
3
vs Industry
9
Median 3Y
13.8
Median 5Y
12.1
Industry
6.5
Forward
10.7
More Details
18.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
18.7
vs History
34
vs Industry
5
Median 3Y
20.5
Median 5Y
16.6
Industry
7
Forward
14.1
More Details
17.3
EV/OCF
EV/OCF
Enterprise Value to OCF
17.3
vs History
22
vs Industry
10
Median 3Y
17.1
Median 5Y
16.1
Industry
7.9
More Details
17.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
17.3
vs History
52
vs Industry
7
Median 3Y
18.9
Median 5Y
17.7
Industry
6.2
More Details
3.7
EV/IC
EV/IC
Enterprise Value to IC
3.7
vs History
0
vs Industry
36
Median 3Y
2.7
Median 5Y
2.7
Industry
5.5
More Details

Multiples Across Competitors

AMGN Competitors Multiples
Amgen Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Amgen Inc
NASDAQ:AMGN
183.3B USD 5.1 26.3 18.7 18.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 012 267.3 -161 655.3 -196 301 -194 061
US
Abbvie Inc
NYSE:ABBV
403.3B USD 6.8 171.9 16.6 23.6
US
Gilead Sciences Inc
NASDAQ:GILD
153.4B USD 5.3 19 12.7 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116B USD 9.9 31.6 23.2 24.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 071.3 -528.5 -575.5 -560.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
76.2B USD 5.4 16.7 15.8 17.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
61.3B USD 24.9 -192.1 -480.9 -330.1
AU
CSL Ltd
ASX:CSL
89.9B AUD 3.8 19.8 13.3 16.5
NL
argenx SE
XBRU:ARGX
48.5B EUR 15.7 36.9 64.1 65.9
US
Seagen Inc
F:SGT
39.3B EUR 20 -61.2 -65.9 -59.5
P/S Multiple
Revenue Growth P/S to Growth
US
Amgen Inc
NASDAQ:AMGN
Average P/S: 3 092 221.4
5.1
4%
1.3
FR
Pharnext SCA
OTC:PNEXF
34 012 267.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
9%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 071.3
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.4
5%
1.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
24.9
44%
0.6
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
15.7
46%
0.3
US
S
Seagen Inc
F:SGT
20
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Amgen Inc
NASDAQ:AMGN
Average P/E: 46
26.3
44%
0.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 655.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
171.9
89%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
19
191%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.6
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -528.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
8%
2.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -192.1 N/A N/A
AU
CSL Ltd
ASX:CSL
19.8
11%
1.8
NL
argenx SE
XBRU:ARGX
36.9
37%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Amgen Inc
NASDAQ:AMGN
Average EV/EBITDA: 23.5
18.7
10%
1.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 301 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
14%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.2
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -575.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.8
9%
1.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -480.9 N/A N/A
AU
CSL Ltd
ASX:CSL
13.3
8%
1.7
NL
argenx SE
XBRU:ARGX
64.1
769%
0.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.9 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Amgen Inc
NASDAQ:AMGN
Average EV/EBIT: 25.6
18.7
19%
1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 061 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.6
30%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
13%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
12%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -330.1 N/A N/A
AU
CSL Ltd
ASX:CSL
16.5
11%
1.5
NL
argenx SE
XBRU:ARGX
65.9
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A N/A

See Also

Summary
AMGN intrinsic value, competitors valuation, and company profile.
DCF Valuation
AMGN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AMGN stock valuation using valuation multiples.
Wall Street Estimates
AMGN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AMGN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 300,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.